KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Debt to Equity (2020 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Debt to Equity for 9 consecutive years, with $0.03 as the latest value for Q4 2025.

  • Quarterly Debt to Equity fell 36.01% to $0.03 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.03 through Dec 2025, down 36.01% year-over-year, with the annual reading at $0.03 for FY2025, 36.01% down from the prior year.
  • Debt to Equity for Q4 2025 was $0.03 at Supernus Pharmaceuticals, up from $0.01 in the prior quarter.
  • The five-year high for Debt to Equity was $0.52 in Q4 2021, with the low at $0.01 in Q3 2025.
  • Average Debt to Equity over 5 years is $0.07, with a median of $0.05 recorded in 2024.
  • The sharpest move saw Debt to Equity skyrocketed 1153.04% in 2021, then plummeted 95.42% in 2022.
  • Over 5 years, Debt to Equity stood at $0.52 in 2021, then tumbled by 95.42% to $0.02 in 2022, then soared by 137.1% to $0.06 in 2023, then dropped by 19.11% to $0.05 in 2024, then plummeted by 36.01% to $0.03 in 2025.
  • According to Business Quant data, Debt to Equity over the past three periods came in at $0.03, $0.01, and $0.03 for Q4 2025, Q3 2025, and Q1 2025 respectively.